The FDA will conduct a safety review of Johnson & Johnson's Regranex after a study found a potential link between the diabetic foot gel and a higher risk of cancer-related deaths. A J&J spokeswoman said the company is working with the FDA and remains "confident in the safety and effectiveness" of the product.

Full Story:
CNNMoney, Reuters

Related Summaries